XWXun Wang

Xun Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xun Wang has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Dong Li

    State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Academy of Military Medical Sciences , Beijing 102206

    5 shared publications
  • Lihong Diao

    State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of lifeomics, Beijing 102206, China

    3 shared publications
  • Yuan Liu

    State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Academy of Military Medical Sciences , Beijing 102206

    3 shared publications
  • Zhongyang Liu

    State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics , Beijing 102206 , China

    3 shared publications
  • Chun-Mei Cao

    Laboratory of Cardiovascular Science, Beijing Clinical Research Institute, Capital Medical University Affiliated Beijing Friendship Hospital, 95 Yongan Road, Xicheng District, Beijing, 100050, China.

    2 shared publications
  • Fuchu He

    State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China

    2 shared publications

Latest Publications

  • Open Access

    TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion–Induced Myocardial Ferroptosis

    by Kun Zhu, Jing Guo, Yangli Liu, Jingchen Li, Xun Wang, Rilei Dai, Xiang Wei, Dingsheng Jiang, Le Gao, Jiaxing Bai, et al.

    BACKGROUND: Myocardial ischemia/reperfusion (I/R) injury is a common and severe clinical complication in patients with ischemic heart disease after reperfusion therapy. Effective therapeutic strategies for myocardial I/R injury remain limited. Ferroptosis is a form of regulated cell death characterized by iron-dependent lipid peroxidation. However, the mechanisms underlying ferroptosis in myocardial I/R injury are not fully understood. METHODS: Transcriptomic data from patients with heart failure and cardiomyocytes undergoing ferroptosis were analyzed. Based on the screening results, TRIM28 (tripartite motif-containing 28) expression was evaluated in ferroptotic cardiomyocytes. Cardiac I/R injury models in mice and hypoxia/reoxygenation injury models in neonatal rat ventricular myocytes were established. To explore the function of TRIM28, we used adeno-associated virus serotype 9 to achieve cardiomyocyte-specific overexpression and generated tamoxifen-inducible cardiomyocyte–specific TRIM28 knockout mice. RNA sequencing, coimmunoprecipitation coupled with mass spectrometry, and ubiquitinome profiling were applied to elucidate the underlying mechanisms. Human heart samples from patients with ischemic heart disease were used to evaluate the expression of TRIM28 and its related signaling molecules. The Connectivity Map database was used to screen potential activators of TRIM28. RESULTS: We found that TRIM28 expression was downregulated in ferroptosis inducer–treated and hypoxia/reoxygenation–injured cardiomyocytes, as well as in I/R-injured mouse hearts. Cardiomyocyte-specific overexpression of TRIM28 protected the heart against I/R-induced ferroptosis, whereas its deficiency exacerbated myocardial I/R-induced ferroptotic injury. Mechanistically, TRIM28 functioned as an E3 ubiquitin ligase that directly bound to IRP2 (iron regulatory protein 2) and promoted K48-linked ubiquitination at the K877 site, leading to the downregulation of IRP2 and TFR1 (transferrin receptor 1), suppression of intracellular iron uptake, and consequent attenuation of cardiomyocyte ferroptosis. Furthermore, p55γ interacted with and upregulated TRIM28, thereby mitigating I/R-induced myocardial ferroptosis. Consistent with these findings, protein levels of TRIM28 and p55γ were decreased in heart samples from patients with ischemic heart disease, whereas IRP2 and TFR1 were increased. Last, we demonstrated that perhexiline inhibited I/R-induced myocardial ferroptosis by upregulating p55γ and TRIM28. CONCLUSIONS: Our study identifies TRIM28 as an essential E3 ubiquitin ligase of IRP2 and delineates that TRIM28-mediated inhibition of myocardial ferroptosis by targeting IRP2-TFR1 signaling protects the heart against I/R injury, indicating that targeting TRIM28 represents a promising therapeutic strategy for suppressing cardiomyocyte ferroptosis and I/R injury.


  • Endothelial SRSF1 Promotes Ischemia-Induced Angiogenesis via ATF3-KLF2-S1PR1 Pathway

    by Wenting Zhu, Ning Xie, Zhenyan Li, Xun Wang, Kuo Bi, Kun Zhu, Rilei Dai, Le Gao, Yufei Wang, Jing Guo, et al.

    BACKGROUND: Peripheral artery disease is a severe ischemic vascular pathology without effective pharmacological approaches and improving angiogenesis to recover blood perfusion is a promising therapeutic strategy. Endothelial cells are the primary cell type contributing to angiogenesis in response to ischemia. However, the molecular mechanisms regulating ischemia-induced angiogenesis remain elusive. METHODS: We used a discovery-driven approach to identify elevated SRSF1 (serine/arginine splicing factor 1) expression in endothelial cells after ischemia. We used loss- and gain-of-function approaches to explore the role of SRSF1 in angiogenesis both in vivo and in vitro. A mouse model of hindlimb ischemia was used to evaluate ischemia-induced angiogenesis. We also investigated the mechanisms through transcriptome, enhanced crosslinking and immunoprecipitation sequencing, RNA pull-down, and chromatin immunoprecipitation–quantitative polymerase chain reaction analysis. RESULTS: Proteomic analyses identified endogenous SRSF1 accumulated in endothelial cells of the ischemic muscle and responded to hypoxia. Mice deficient in endothelial SRSF1 exhibited impaired blood flow recovery and impaired vasculature formation after hindlimb ischemia. Importantly, overexpression of SRSF1 enhanced blood flow recovery and angiogenesis after hindlimb ischemia. SRSF1 overexpression enhanced the angiogenic functions of human endothelial cells, promoting tube formation, sprouting capability, and cell migration, while SRSF1 knockdown suppressed these functions. Mechanistically, SRSF1 modulated the alternative splicing of ATF3 (activating transcription factor 3) by directly binding to ATF3 pre-mRNA (precursor messenger RNA), and SRSF1 overexpression elevated full-length ATF3 transcript at the expense of truncated ATF3Δzip2 transcript. ATF3 then bound directly to the KLF2 (Krüppel-like factor 2) promoter, suppressed KLF2 expression and downstream S1PR1 (sphingosine-1-phosphate receptor 1) signaling. Through upregulation of full-length ATF3 and downregulating KLF2-S1PR1 signaling, SRSF1 promoted endothelial tube formation and angiogenesis. In addition, alprostadil, the prostaglandin E1 analog, could activate the SRSF1 signaling to improve endothelial angiogenesis in vitro and in vivo. CONCLUSIONS: Our findings identified SRSF1 as a novel regulator of ischemia-induced angiogenesis that enhances endothelial angiogenic functions by regulating the ATF3-KLF2-S1PR1 pathway. These results suggest that modulation of endothelial SRSF1 may represent a promising therapeutic approach for treating ischemic vascular diseases.


  • Open Access

    An integrated computational strategy to predict personalized cancer drug combinations by reversing drug resistance signatures

    by Xun Wang, Lele Yang, Chuang Yu, Xinping Ling, Congcong Guo, Ruzhen Chen, Dong Li, Zhongyang Liu


  • Open Access

    UbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase/deubiquitinase–substrate interactions in eukaryotic species

    by Xun Wang, Yang Li, Mengqi He, Xiangren Kong, Peng Jiang, Xi Liu, Lihong Diao, Xinlei Zhang, Honglei Li, Xinping Ling, et al.

    As an important post-translational modification, ubiquitination mediates ∼80% of protein degradation in eukaryotes. The degree of protein ubiquitination is tightly determined by the delicate balance between specific ubiquitin ligase (E3)-mediated ubiquitination and deubiquitinase-mediated deubiquitination. In 2017, we developed UbiBrowser 1.0, which is an integrated database for predicted human proteome-wide E3–substrate interactions. Here, to meet the urgent requirement of proteome-wide E3/deubiquitinase–substrate interactions (ESIs/DSIs) in multiple organisms, we updated UbiBrowser to version 2.0 (http://ubibrowser.ncpsb.org.cn). Using an improved protocol, we collected 4068/967 known ESIs/DSIs by manual curation, and we predicted about 2.2 million highly confident ESIs/DSIs in 39 organisms, with >210-fold increase in total data volume. In addition, we made several new features in the updated version: (i) it allows exploring proteins’ upstream E3 ligases and deubiquitinases simultaneously; (ii) it has significantly increased species coverage; (iii) it presents a uniform confidence scoring system to rank predicted ESIs/DSIs. To facilitate the usage of UbiBrowser 2.0, we also redesigned the web interface for exploring these known and predicted ESIs/DSIs, and added functions of ‘Browse’, ‘Download’ and ‘Application Programming Interface’. We believe that UbiBrowser 2.0, as a discovery tool, will contribute to the study of protein ubiquitination and the development of drug targets for complex diseases.


  • Open Access

    CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response

    by Zhongyang Liu, Jiale Liu, Xinyue Liu, Xun Wang, Qiaosheng Xie, Xinlei Zhang, Xiangya Kong, Mengqi He, Yuting Yang, Xinru Deng, et al.

    To date, only some cancer patients can benefit from chemotherapy and targeted therapy. Drug resistance continues to be a major and challenging problem facing current cancer research. Rapidly accumulated patient-derived clinical transcriptomic data with cancer drug response bring opportunities for exploring molecular determinants of drug response, but meanwhile pose challenges for data management, integration, and reuse. Here we present the Cancer Treatment Response gene signature DataBase (CTR-DB, http://ctrdb.ncpsb.org.cn/), a unique database for basic and clinical researchers to access, integrate, and reuse clinical transcriptomes with cancer drug response. CTR-DB has collected and uniformly reprocessed 83 patient-derived pre-treatment transcriptomic source datasets with manually curated cancer drug response information, involving 28 histological cancer types, 123 drugs, and 5139 patient samples. These data are browsable, searchable, and downloadable. Moreover, CTR-DB supports single-dataset exploration (including differential gene expression, receiver operating characteristic curve, functional enrichment, sensitizing drug search, and tumor microenvironment analyses), and multiple-dataset combination and comparison, as well as biomarker validation function, which provide insights into the drug resistance mechanism, predictive biomarker discovery and validation, drug combination, and resistance mechanism heterogeneity.


  • Open Access

    DCABM-TCM, a Database of Constituents Absorbed into Blood and Metabolites of Traditional Chinese Medicine

    by Xinyue Liu, Jinying Liu, Feng Xu, Runa Li, Lin Xing, Liying Yuan, Shuzhen Guo, Feifei Guo, Yuan Liu, Jiale Liu, et al.

    Traditional Chinese Medicine (TCM) not only maintains the health of peoples in Asia but also provides a great resource of active natural products for modern drug development. However, owing to its diverse constituents and the complex interactions with the human body, it is still challenging to clarify its effective constituents and molecular mechanism. This greatly hinders its widespread application worldwide and TCM-based modern drug development. The vast majority of constituents in TCM can produce pharmacological effects only after they are absorbed into bloodstream. Compared with ordinary constituents generally detected in vitro, these that are verified to reach the bloodstream, including original constituents absorbed into blood and metabolites of original constituents produced by the gastrointestinal tract, intestinal microflora, and liver, are more likely to be really effective ones responsible for the pharmacological effects. Here we developed DCABM-TCM (a Database of Constituents Absorbed into Blood and Metabolites of TCM), the first database systematically collecting blood constituents of TCM prescriptions and herbs, including prototypes and metabolites experimentally-detected in blood, together with the corresponding detailed detection conditions by manual literature mining. Currently DCABM-TCM has collected 4206 blood constituents of 192 prescriptions and 194 herbs, and also integrated various related annotations including physicochemical properties, ADMET properties, and associated targets, functional terms, pathways, and diseases etc. Furthermore, DCABM-TCM supported two analysis functions, the network pharmacology analysis for TCM molecular mechanism elucidation and the target/pathway/disease-based screening of candidate blood constituents, herbs or prescriptions for TCM-based drug discovery. DCABM-TCM is freely assessable by http://bionet.ncpsb.org.cn/dcabm-tcm/ and is browsable and searchable for each of 6 kinds of entities, including prescriptions, herbs, blood constituents, targets, pathways, and diseases. DCABM-TCM will contribute to not only the elucidation of effective constituents and molecular mechanism of TCMs but also the discovery of TCM-derived drug-like compounds which are both bioactive and bioavailable, the feature investigation of absorbable natural compounds, and the quality control of herbs.


  • Open Access

    FibroAtlas: A Database for the Exploration of Fibrotic Diseases and Their Genes

    by Jinying Liu, Dezhi Sun, Jiale Liu, Hao Xu, Yuan Liu, Yang Li, Lihong Diao, Xun Wang, Dan Wang, Lei Tian, et al.

    Background. Fibrosis is a highly dynamic process caused by prolonged injury, deregulation of the normal processes of wound healing, and extensive deposition of extracellular matrix (ECM) proteins. During fibrosis process, multiple genes interact with environmental factors. Over recent decades, tons of fibrosis-related genes have been identified to shed light on the particular clinical manifestations of this complex process. However, the genetics information about fibrosis is dispersed in lots of extensive literature.Methods. We extracted data from literature abstracts in PubMed by text mining, and manually curated the literature and identified the evidence sentences.Results. We presented FibroAtlas, which included 1,439 well-annotated fibrosis-associated genes. FibroAtlas 1.0 is the first attempt to build a nonredundant and comprehensive catalog of fibrosis-related genes with supporting evidence derived from curated published literature and allows us to have an overview of human fibrosis-related genes.